OrbiMed’s Orchestra BioMed OBIO Stock Holding History

OrbiMed’s Portfolio OBIO Stock Details OBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-500,000	Closed	-$5.04M	–	161
2021 Q4	$5.04M	Hold	500,000	–	–	0.06%	135
2021 Q3	$4.95M	Hold	500,000	–	–	0.05%	153
2021 Q2	$5.1M	Hold	500,000	–	–	0.05%	147
2021 Q1	$5.59M	Hold	500,000	–	–	0.05%	138
2020 Q4	$6.41M	Hold	500,000	–	–	0.06%	136
2020 Q3	$5.5M	Buy	+500,000	New	+$5.61M	0.07%	124

Other funds holding OBIO

DKCM

Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

SCM

Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Amitell Capital Singapore $109M AUM 50.64% 1-Year Est. Return

Sculptor Capital New York $12.3B AUM 40.26% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

OrbiMed's OBIO Position: Q1 2022 in Review

OrbiMed sold out of Orchestra BioMed (OBIO) in Q1 2022, closing a stake of 500,000 shares — an estimated $5.04M sold.

OrbiMed first reported a position in OBIO in Q3 2020 and held it in 6 quarters. The position peaked at $6.41M in Q4 2020. 59 funds tracked by Wall St. Rank hold OBIO as of Q1 2022.

OrbiMed reported no remaining Orchestra BioMed position as of Q1 2022 after selling out during the quarter.
OrbiMed sold 500,000 Orchestra BioMed shares in Q1 2022, an estimated $5.04M.
OrbiMed first reported a position in Orchestra BioMed in Q3 2020 and held it in 6 quarters.
OrbiMed's Orchestra BioMed position peaked at $6.41M in Q4 2020.
59 funds tracked by Wall St. Rank held Orchestra BioMed as of Q1 2022.

Based on OrbiMed's 13F filing for Q1 2022, filed 16 May 2022.